FHTX
Foghorn Therapeutics Inc.
Next earnings Aug 3, 2026 (before open) · consensus $-0.26 EPS, $7.04M rev
Last earnings -10.3% on 2026-05-07
$4.22
▲ +4.71%$4.22▼ -13.70%
over 1Y
L $3.53EODHDH $6.68
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.7%
1W+1.0%
1M-1.2%
3M-6.2%
YTD-18.7%
1Y-13.7%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 16 analysts
Strong Buy
Revenue grew 36.8% YoY; but unprofitable (net margin -240.3%).
Revenue (FY2025) $30.9M · FY2025
Foghorn Therapeutics Inc. shows $30.9M in FY2025 revenue (+36.8% YoY), a -240.3% net margin.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $1.32M | $19.2M | $34.2M | $22.6M | $30.9M |
| Gross profit | — | — | — | — | — |
| Operating income | -$101M | -$117M | -$108M | -$103M | -$86.4M |
| Net income | -$101M | -$109M | -$98.4M | -$86.6M | -$74.3M |
| Diluted EPS | -$2.73 | -$2.62 | -$2.34 | -$1.58 | -$1.18 |
| Net margin | -7681.6% | -566.3% | -288.2% | -383.2% | -240.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$171M
EV / EBITDA—
EV / Sales5.5
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-30.0%
FCF yield-34.8%
Quality & risk
ROIC (est.)—
Free cash flow-$86.1M
Total debt$4.15M
Net cash$76.7M
Altman Z-Score-4.64 distress
Piotroski F-Score2/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+5.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-242026-06-25open ↗4Period ending 2026-06-242026-06-25open ↗4Period ending 2026-06-242026-06-25open ↗4Period ending 2026-06-242026-06-25open ↗4Period ending 2026-06-242026-06-25open ↗4Period ending 2026-06-242026-06-25open ↗4Period ending 2026-06-242026-06-25open ↗4Period ending 2026-06-242026-06-25open ↗4Period ending 2026-06-242026-06-25open ↗8-KPeriod ending 2026-06-242026-06-24open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-14open ↗
Frequently asked
- Is Foghorn Therapeutics Inc. (FHTX) a buy?
- FHTX currently carries a Avoid rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 36.8% YoY; but unprofitable (net margin -240.3%).
- What is Foghorn Therapeutics Inc.'s quality score?
- FHTX scores 39.52941176470588/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001822462, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 7:49:37 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.